Sangamo Therapeutics, Inc. (SGMO) Financial Analysis & Valuation | Quarter Chart

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP)... more
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science i... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$30.66MExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOAlexander D. Macrae Ch.B
IPO Date2000-04-06CAGR15.33%
Employees127Websitewww.sangamo.com
Div. Yield—Payout Ratio—
Buy Back Yield—Total Yield—
SGMO chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$34.08MP/E-0.2Forward P/E—PEG—
P/S—P/B—P/CF—P/FCF—
Sales$34.56MSales 1Y-45.8%Sales 3Y-85.66%Sales 5Y-73.7%
EPS$-0.37EPS 1Y—EPS 3Y—EPS 5Y—
Sales QoQ-89.87%EPS QoQ-27.27%Sales QoQ Avg586.64%EPS QoQ Avg-7.58%
Gross Margin100%Operating Margin-319.25%Profit Margin-356.89%ROCE-1615.02%
ROA-206%ROE6686%Altman Z Score-44.45Piotroski Score1
Current Ratio0.7Quick Ratio0.7Cash Ratio0.52Op. CF Ratio-0.36
Debt/Equity-1.02Debt/Assets0.32Lt Debt/Equity-1.02Lt Debt/Cap.51.28
Intrst Cov.—Inventory Turnover—Asset Turnover0.58Receivables Turnover39.58
Enterprise Value$34.08MP/E Ratio-0.2
Forward P/E—PEG Ratio—
P/S Ratio—P/B Ratio—
P/CF Ratio—P/FCF Ratio—
EPS$-0.37EPS Growth 1Y—
EPS Growth 3Y—EPS Growth 5Y—
Revenue Growth 1Y-45.8%Gross Margin100%
Operating Margin-319.25%Profit Margin-356.89%
ROE6686%ROA-206%
ROCE-1615.02%Current Ratio0.7
Quick Ratio0.7Cash Ratio0.52
Debt/Equity-1.02Interest Coverage—
Altman Z Score-44.45Piotroski Score1